Business Wire

Medidata Solutions to Host Annual European NEXT Conference Series

Jaa

Medidata Solutions (NASDAQ:MDSO), is pleased to announce the 13th annual NEXT Conference series will commence in Europe in March 2018, with events in Basel (March 7), Frankfurt (March 21) and London (April 25-26). Industry experts in drug and device development, clinical operations, data management, biostatistics and digital medicine innovation will gather for the largest customer conference series of its kind, as more than 3,000 professionals attended events in Europe, Asia and the US last year.

Attendees from across the continent will have a unique opportunity to share best practices and network with industry peers. Medidata Solutions experts will discuss trends that will drive efficiencies for the drug and medical device development industry. The event series will feature interactive, hands-on learning opportunities to design, execute, manage and monitor the next generation of clinical research.

“We value the opportunity to network and learn from leaders across the healthcare sector at Medidata NEXT events,” said Sachin Bharadia, Director of Clinical Data Management at Zifo RnD Solutions. “It provides an effective platform to examine how technological advances are changing best practices and transforming clinical research to improve efficiencies and accelerate drug development in order to bring important new medicines to patients across the world.”

Thought provoking sessions will be led by global life sciences organizations, industry experts and Medidata executives. Each event is comprised of a rich, unique agenda, which can be found here.

“Medidata Solutions is in its 13th year of hosting the NEXT conference series, which continues to bring together life science professionals from around the world to evaluate how technology is revolutionizing drug development,” said Christian Hebenstreit, General Manager EMEA, Medidata. “It also provides the opportunity for attendees to obtain first-hand experience of how our intelligent, unified platform is pushing scientific innovation to simplify complex clinical trial processes, accelerate research programs and drive better clinical outcomes. We look forward to kicking off the series in Basel on March 7.”

Medidata NEXT EMEA events are free to attend. For further details of the events and to register, please visit http://medidatanext.com/.

About Medidata Solutions

Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com.

Contact information

Medidata Solutions
Investor :
Betsy Frank, +1 917-522-4620
bfrank@mdsol.com
or
Anthony D’Amico, +1 732-767-4331
adamico@mdsol.com
or
Media :
Erik Snider, +1 646-362-2997
esnider@mdsol.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Intesa Sanpaolo Turns to Gemalto for Italy’s First Biometric Contactless Payment Card Pilot19.12.2018 09:00Tiedote

Gemalto, the leader in digital security, is supplying Intesa Sanpaolo, the number one banking group in ltaly, with the first Mastercard biometric contactless payment card. The pilot promoted by Intesa Sanpaolo and Mastercard allows to test an EMV contactless biometric card for the first time in Europe. Consumers may simply tap their card to any POS terminal to pay and authorize the transaction with their fingerprint, combining a fast and convenient user experience to an advanced cardholder authentication approach. In addition, the card works without a battery as it’s powered by the terminal which means that there is no limit on the number of transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005481/en/ Biometric payment card (Photo: Gemalto) Enhanced contactless payment working with existing infrastructure Intesa Sanpaolo’s initiative is the latest step forward in the bank’s ambitious digital transformation s

Agreement Between Human Horizons, Wuxi Weifu e-Drive Technology and Protean Electric Will Deliver Mass Produced In-Wheel Motors for Intelligent Connected Vehicles19.12.2018 08:01Tiedote

Human Horizons, the mobility technology innovator, Protean Electric Ltd, the automotive technology company, and Wuxi Weifu e-Drive Technology Ltd. (“WFDT”) are pleased to announce their memorandum of strategic co-operation to develop and manufacture in-wheel motors for the next generation of intelligent connected vehicles. The co-operation brings together some of the most technologically advanced and innovative companies in the automotive sector. A dedicated team and production facility will be created in China to deliver in-wheel motors at scale, simplifying production systems, reducing development lead times and accelerating the benefits that in-wheel motors bring to the market for future transport solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005879/en/ Mark Stanton, CTO of Human Horizons and Wang Xiaodong, Deputy Chairman of Weifu High-Technology Group Ltd signed the memorandum of strategic cooperation

Akaal Pharma Pty Ltd Announces Licensing Agreement for its First-in-Class, Topical Spingosine-1-Phosphate-1 (S1P1) Receptor Modulator for Atopic Dermatitis and Psoriasis19.12.2018 02:56Tiedote

Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has entered into a licensing agreement for Akaal Pharma’s First-in-Class, topical Spingosine-1-Phosphate-1 (S1P1) modulator, AKP-11, with Boston Pharmaceuticals, Inc. (Boston Pharmaceuticals). AKP-11 is a differentiated S1P1 modulator, which potentially has clinical applications in a number of inflammatory, immune and vascular diseases. Akaal Pharma has demonstrated the clinical activity of AKP-11 in multiple Phase-1 clinical studies. Under the terms of the license, Boston Pharmaceuticals is responsible for the further clinical development and commercialisation of AKP-11 for the Americas and Europe. Akaal Pharma has the rights for the rest of the world. Financial terms of the agreement were not disclosed. "We continue to actively prioritize and expand our dermatology and pain programs to serve the wider global community suffering from these diseases and where there is need of safe and effective treatment,” said Chairman of

Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange19.12.2018 01:33Tiedote

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the listing and trading of its American Depositary Shares (“ADSs”) on the New York Stock Exchange (“NYSE”) is expected to commence on December 24, 2018. Takeda’s ADSs currently trade over-the-counter. The ADSs will now trade under the ticker symbol “TAK” and The Bank of New York Mellon will continue to act as the depositary bank for the ADS program. Takeda will maintain its headquarters in Japan and its primary listing on the Tokyo Stock Exchange (the “TSE”), as well as its current listings on local Japanese stock exchanges. “Our dual listing on the NYSE and TSE reflects our position as a leading global biopharmaceutical company and will provide wider capital markets access with expanded trading hours for our in

Sestek Speech Analytics Scores the Highest Overall Vendor Satisfaction Mark from Customers in DMG Consulting Survey18.12.2018 22:00Tiedote

Sestek today announced that it was recognized for getting the highest overall vendor satisfaction rating from customers in DMG Consulting’s 2018 – 2019 Speech Analytics Product and Market Report. Compared to the featured competitors, Sestek Speech Analytics achieved the highest customer ratings in 8 major vendor categories out of 10. Here are the 7 categories in which Sestek Speech Analytics received a perfect score of 5.0 by the customer satisfaction ratings: • Training and workshops • Ongoing service and support • Professional services • Innovation • Responsiveness to product enhancement requests • Vendor communication • Overall vendor satisfaction Donna Fluss, the President of DMG Consulting -providing comprehensive coverage and authoritative analysis for the market- stated the importance of speech analytics: “Speech analytics has always been interesting because of its unique contributions to the understanding of voice interactions in the contact center. Companies that invest in the

Brand Marketing and Social Purpose Veteran Larry Koffler Joins BCW18.12.2018 21:31Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Larry Koffler has joined as Executive Vice President, Managing Director in the agency’s Brand Solutions Practice in New York. He will join BCW on January 14, 2019. “Larry has had an extraordinary career leading integrated communications programs that bridge brand, corporate and purpose for some of the world’s most iconic brands and organizations,” said Chris Foster, President, North America, BCW. “His award-winning experience across a wide variety of industries will be invaluable to clients – and in particular purpose-driven clients – that need powerful programs that exceed expectations and drive meaningful results. I am excited for what he will add to BCW’s celebrated brand solutions business.” Koffler will report to Thomas Bunn, Executive Vice President, Managing Director, Brand Solutions. Koffler joins BCW from Edelman, where he spent the entirety of his career and most recently served as Executi

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme